Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

ConclusionsIpragliflozin was well tolerated, effective, and reduced bodyweight over a period of 52  weeks in patients treated with insulin with/without a DPP-4 inhibitor.Clinicaltrials.gov identifierNCT02175784
Source: Diabetology International - Category: Endocrinology Source Type: research